New drug approved by FDA for metastatic prostate cancer
Wednesday 8 June 2011
The US Food and Drug Administration (FDA) has approved abiraterone acetate (Zytiga, Cougar Biotechnology) in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer in men who have received prior docetaxel chemotherapy. The drug was found to prolong the lives of men with advanced prostate cancer who had received prior treatments.
>> http://www.medscape.com/viewarticle/741780?sssdmh=dm1.683869&src=nldne
European Oncology Nursing SocietyAvenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu